Page last updated: 2024-12-07

inositol 2,4,5-trisphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Inositol 2,4,5-trisphosphate (IP3) is a second messenger molecule involved in signal transduction. It is generated by the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C (PLC) in response to various stimuli, including hormones, neurotransmitters, and growth factors. IP3 binds to and activates IP3 receptors, which are calcium channels located on the endoplasmic reticulum (ER). This binding triggers the release of calcium ions from the ER into the cytoplasm, leading to a rise in intracellular calcium concentration. The increase in calcium levels initiates various cellular processes, including muscle contraction, secretion, cell growth, and apoptosis. IP3 is a key component of the calcium signaling pathway, and its dysregulation is implicated in various diseases, such as cancer, neurodegenerative disorders, and cardiovascular diseases. IP3 is extensively studied to understand its role in cell signaling, its involvement in disease pathogenesis, and its potential as a therapeutic target.'

Cross-References

ID SourceID
PubMed CID122195
MeSH IDM0173205

Synonyms (14)

Synonym
I2P ,
d-myo-inositol-2,4,5-trisphosphate
d-myo-inositol-2,4,5-triphosphate
inositol 2,4,5 trisphosphate
inositol 2,4,5-trisphosphate
DB03956
91840-07-2
inositol 2,4,5-triphosphate
(2,4,5)ip(3)
ins(2,4,5)p(3)
inositol-2,4,5-trisphosphate
2,4,5-ip3
(1r,2r,3s,4s,5s,6s)-3,5,6-trihydroxycyclohexane-1,2,4-triyl tris[dihydrogen (phosphate)]
Q27461316

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" If this was due either to some conversion of added Ins(1,3,4,5)P4 into Ins(1,4,5)P3 by the 3-phosphatase, or to Ins(1,3,4,5)P4 acting as a weak (or partial) agonist on the InsP3 receptor it would be expected that,in the presence of thimerosal to sensitize the InsP3 receptor, the dose-response curve to Ins(1,3,4,5)P4 would be left-shifted by the same extent as that of Ins(1,4,5)P3."( Synergistic effects of inositol 1,3,4,5-tetrakisphosphate on inositol 2,4,5-triphosphate-stimulated Ca2+ release do not involve direct interaction of inositol 1,3,4,5-tetrakisphosphate with inositol triphosphate-binding sites.
Cullen, PJ; Dawson, AP; Dreikausen, UE; Irvine, RF; Loomis-Husselbee, JW, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's27 (67.50)18.2507
2000's10 (25.00)29.6817
2010's2 (5.00)24.3611
2020's1 (2.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.64 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]